loading page

Minimal residual disease detection with circulating tumor DNA in colorectal cancer: current horizons and future perspectives in clinical applications
  • +2
  • Tianhao Mu,
  • Ming Liu,
  • Mingyan Xu,
  • Jia Gu,
  • Shifu Chen
Tianhao Mu
Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences
Author Profile
Ming Liu
HaploX Biotechnology
Author Profile
Mingyan Xu
HaploX Biotechnology
Author Profile
Jia Gu
City University of Macau
Author Profile
Shifu Chen
Shenzhen Institutes of Advanced Technology Chinese Academy of Sciences

Corresponding Author:[email protected]

Author Profile

Abstract

Colorectal cancer (CRC) remains a significant health concern in the world. The existing standard of care guidelines for CRC surveillance falls short of effectively and timely detecting recurrence or metastasis. In recent years, circulating tumor DNA (ctDNA) has emerged as a promising material for minimal residual disease (MRD) detection. In this paper, we provide an exhaustive review of the methods utilized for MRD detection via ctDNA, present evidence supporting the potential of ctDNA MRD as a valuable biomarker in clinical applications, and engage in a discussion regarding ongoing ctDNA MRD based clinical trials in CRC. Lastly, we offer insights into future prospects of ctDNA-based MRD methodological advancements and clinical research. It’s foreseeable that more sensitive, flexible, and economic MRD detection methods will emerge with the deeper research on cfDNA genomics, fragmentomics, methylomes, and nucleosome imprinting. At the same time, MRD-guided intervention study will evolve for revolutionizing the treatment paradigm of CRC.
Submitted to Cancer Reports
Submission Checks Completed
Assigned to Editor
Reviewer(s) Assigned
03 Jul 2024Review(s) Completed, Editorial Evaluation Pending
07 Jul 2024Reviewer(s) Assigned